Co-Authors
This is a "connection" page, showing publications co-authored by Ritesh Gupta and Anoop Misra.
Connection Strength
7.692
-
Heterogeneity in presentation of hyperglycaemia during COVID-19 pandemic: A proposed classification. Diabetes Metab Syndr. 2021 Jan-Feb; 15(1):403-406.
Score: 0.927
-
Clinical considerations in patients with diabetes during times of COVID19: An update on lifestyle factors and antihyperglycemic drugs with focus on India. Diabetes Metab Syndr. 2020 Nov-Dec; 14(6):1777-1781.
Score: 0.902
-
COVID19 in South Asians/Asian Indians: Heterogeneity of data and implications for pathophysiology and research. Diabetes Res Clin Pract. 2020 Jul; 165:108267.
Score: 0.886
-
Diabetes and COVID-19: evidence, current status and unanswered research questions. Eur J Clin Nutr. 2020 Jun; 74(6):864-870.
Score: 0.882
-
Contentious issues and evolving concepts in the clinical presentation and management of patients with COVID-19 infectionwith reference to use of therapeutic and other drugs used in Co-morbid diseases (Hypertension, diabetes etc). Diabetes Metab Syndr. 2020 May - Jun; 14(3):251-254.
Score: 0.874
-
Clinical considerations for patients with diabetes in times of COVID-19 epidemic. Diabetes Metab Syndr. 2020 May - Jun; 14(3):211-212.
Score: 0.871
-
Case of acute unilateral emphysematous pyelonephritis and bacteraemia on treatment with canagliflozin. Postgrad Med J. 2018 12; 94(1118):714-715.
Score: 0.800
-
Glycemic parameters in patients with new-onset diabetes during COVID-19 pandemic are more severe than in patients with new-onset diabetes before the pandemic: NOD COVID India Study. Diabetes Metab Syndr. 2021 Jan-Feb; 15(1):215-220.
Score: 0.230
-
Effects of nationwide lockdown during COVID-19 epidemic on lifestyle and other medical issues of patients with type 2 diabetes in north India. Diabetes Metab Syndr. 2020 Sep - Oct; 14(5):917-920.
Score: 0.221
-
Reply to the letter of Mahajan and Gaur in response to the article: Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers (Singh et al.). Diabetes Metab Syndr. 2020 Sep - Oct; 14(5):729.
Score: 0.221
-
Roadblock in application of telemedicine for diabetes management in India during COVID19 pandemic. Diabetes Metab Syndr. 2020 Jul - Aug; 14(4):577-578.
Score: 0.220
-
Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers. Diabetes Metab Syndr. 2020 Jul - Aug; 14(4):283-287.
Score: 0.219
-
Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab Syndr. 2020 Jul - Aug; 14(4):303-310.
Score: 0.219
-
Telemedicine for diabetes care in India during COVID19 pandemic and national lockdown period: Guidelines for physicians. Diabetes Metab Syndr. 2020 Jul - Aug; 14(4):273-276.
Score: 0.219